Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28041939 | 0.82 | FDPS (0.40) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL6007639 | 0.80 | FDPS (0.41) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL2451018 | 0.80 | FDPS (0.44) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL1079073 | 0.78 | FDPS (0.50) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL4129648 | 0.75 | DPP4 (0.38) | FDPS | |
| SCHEMBL27566007 | 0.75 | FDPS (0.42) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL10857669 | 0.74 | FDPS (0.54) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL28817988 | 0.74 | FDPS (0.54) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL4859275 | 0.74 | FDPS (0.37) | FDPSHDAC1HDAC6LTA4HCYP1A2 | |
| SCHEMBL10726415 | 0.74 | FDPS (0.40) | FDPSHDAC1HDAC6LTA4HCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-14 | — | — | US | claimed |
| EP-3131914-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2017-02-22 | — | — | EP | claimed |
| EP-1292603-B1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| EP-3083654-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-09-29 | — | — | US | claimed |
| US-9192621-B2 | Esters and malonates of SATE prodrugs | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-24 | — | — | US | claimed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| US-20050137161-A1 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC | 2005-06-23 | — | — | US | claimed |
| US-6855821-B2 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, LTD. (US) | 2005-02-15 | — | — | US | claimed |
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | IDENIX PHARMACEUTICALS LLC | 2005-02-10 | — | — | US | claimed |
| US-20040254141-A1 | 2'-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | claimed |
| US-20040181051-A1 | Process for the production of 3'-nucleoside prodrugs | STORER RICHARD (GB) | 2004-09-16 | — | — | US | claimed |
| WO-2004058792-A1 | PROCESS FOR THE PRODUCTION OF 3'-NUCLEOSIDE PRODRUGS | IDENIX (CAYMAN) LIMITED (KY) | 2004-07-15 | — | — | WO | claimed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | claimed |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, INC. | 2004-05-06 | — | — | US | claimed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992010496-A1 | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | PNP, NSUN2, RNGTT | FDPS 923/4885HDAC1 4414/4885HDAC6 3805/4885 |
| US-20050137161-A1 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | FDPS 1831/4885HDAC1 1219/4885HDAC6 828/4885 |
| US-20040254141-A1 | 2'-Fluoronucleosides | NSUN2, PNP, FDPS | FDPS 3/4885HDAC1 2599/4885HDAC6 3946/4885 |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | ZC3HAV1, HAVCR2, NSUN2 | FDPS 947/4885HDAC1 3425/4885HDAC6 2600/4885 |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | NUDT1, PNP, DPYD | FDPS 276/4885HDAC1 4387/4885HDAC6 4717/4885 |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | FDPS 3013/4885HDAC1 3016/4885HDAC6 2536/4885 |
| US-20040181051-A1 | Process for the production of 3'-nucleoside prodrugs | PNP, GART, UMPS | FDPS 114/4885HDAC1 1362/4885HDAC6 830/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | FDPS 2970/4885HDAC1 3021/4885HDAC6 2467/4885 |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | NSUN2, NSUN3, ZC3HAV1 | FDPS 1310/4885HDAC1 1315/4885HDAC6 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.